Abstract: The present disclosure relates to a method for treating a cancer and/or cancer metastasis in a subject comprising administering to the subject irinotecan loaded in a mesoporous silica nanoparticle. The present disclosure also provides a conjugate comprising an agent loaded in a mesoporous silica nanoparticle (MSN) defining at least one pore and having at least one functional group on a sidewall of the at least one pore.

Abstract: The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.

Abstract: The disclosure provides a method for delivering an agent to posterior segment of an eye comprising administrating a pharmaceutical composition comprising the agent and mesoporous silica nanoparticles to the eye. An eye drop and a method for treating an ocular disease in a subject in need of such treatment are also provided.

Abstract: The present disclosure relates to mesoporous silica nanoparticles having modifications on the surface of the (extended) mesopores, which can be further loaded with one or more types of bioactive ingredients within the (extended) mesopores mesopores, processes of preparing the same and applications of the same.